Head-To-Head Comparison: Quantum Genomics (OTCMKTS:QNNTF) versus C4 Therapeutics (NASDAQ:CCCC)

C4 Therapeutics (NASDAQ:CCCC) and Quantum Genomics (OTCMKTS:QNNTF) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Valuation and Earnings

This table compares C4 Therapeutics and Quantum Genomics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.58 million	5.53	-$105.32 million	($1.67)	-1.22
Quantum Genomics	N/A	N/A	N/A	N/A	N/A

Quantum Genomics has lower revenue, but higher earnings than C4 Therapeutics.

Profitability

This table compares C4 Therapeutics and Quantum Genomics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-395.51%	-64.40%	-38.69%
Quantum Genomics	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for C4 Therapeutics and Quantum Genomics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1	2	6	0	2.56
Quantum Genomics	0	0	0	0	0.00

C4 Therapeutics presently has a consensus price target of $7.25, suggesting a potential upside of 257.14%. Given C4 Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe C4 Therapeutics is more favorable than Quantum Genomics.

Insider and Institutional Ownership

78.8% of C4 Therapeutics shares are held by institutional investors. 8.7% of C4 Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

C4 Therapeutics has a beta of 2.93, meaning that its share price is 193% more volatile than the S&P 500. Comparatively, Quantum Genomics has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500.

Summary

C4 Therapeutics beats Quantum Genomics on 7 of the 10 factors compared between the two stocks.

About C4 Therapeutics

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

About Quantum Genomics

Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs. The company also is involved in the development of drugs for the treatment of high blood pressure as monotherapy and the prevention, as well as treatment of heart failure. Quantum Genomics Société Anonyme was incorporated in 2005 and is based in Paris, France.